Combination of PD-1/PD-L1 Checkpoint Inhibition and Dendritic Cell Therapy in Mice Models and in Patients with Mesothelioma

Scientists investigated the efficacy of a combination of anti-PD1/PD-L1 and dendritic cell therapy to optimally induce effective anti-tumor immunity in malignant pleural mesothelioma in both humans and mice.